An anonymous reader quotes a report from The Guardian: Miniature human organs and other tissues are to be grown from NHS patients' cells in a drive to improve medicine testing and reduce the number of animals used in drug development. Scientists will use the clumps of tissue to learn how diseases vary between patients, helping them identify which treatments are best for different people based on the particular pathology underlying their condition. The move marks a shift away from the traditional use of animals as models for human disease, towards what researchers believe will be more accurate and reliable tests based directly on human tissues. Researchers have been growing tiny clumps of human organs, known as organoids, for more than a decade. Tests show that pieces smaller than a millimeter can mirror key features of full-scale organs and tissues, including how they falter with disease and respond to drugs. Armed with organoids grown from diseased human tissues, scientists can investigate whether new drug candidates reverse pathological changes in all or a subset of patients, and quickly identify ineffective drugs early in the process. Historically, more than 90% of drugs that clear animal testing go on to fail in human trials, raising questions about the value of the tests. US and European medicines regulators now encourage other approaches if available. "It's going to have a major impact on the numbers of animals used and the way we develop new drugs in the future," said Matthias Zilbauer, a clinical professor of paediatric gastroenterology at the Cambridge Stem Cell Institute. "We're not saying there won't be any animal use in the near or foreseeable future, because there are still certain issues that cannot be tested in these new models, but the reduction is very real." "A lot of human diseases either do not occur in animals or occur in a different way because they're not human," added Zilbauer. "We want tests and models that can tell us which treatments work, and in what patients, and a mouse cannot tell us that."

Read more of this story at Slashdot.

Longtime Slashdot reader sbinning shares a press release: The U.S. Department of Veterans Affairs announced the launch of a new clinical trial to evaluate the effectiveness and safety of psilocybin to treat major depression in Veterans, including those with concurrent PTSD. The new trial comes after a recent executive order on "Accelerating Medical Treatments for Serious Mental Illness," which aims to increase clinical trial participation and accelerate innovative research models and drug approvals for psychedelic drugs. [...] The randomized, controlled trial will enroll Veterans diagnosed with treatment-resistant major depressive disorder, with or without concurrent PTSD, and will compare outcomes between two psilocybin dosage levels. The study will also assess participants' levels of depression before and after treatment, tolerability of side effects, and overall patient-reported depression. [...] In addition to this trial, VA is involved in 20 active clinical trials focused on psychedelic therapies for mental health conditions. All VA research -- including research into psychedelics -- is conducted under strict safety protocols and in full compliance with federal guidelines.

Read more of this story at Slashdot.

An anonymous reader quotes a report from the BBC: England is on track to become one of the first countries in the world to eliminate hepatitis C, a dangerous virus that attacks the liver, figures show. The target of treating 80% of all known cases has already been met, and deaths from the virus have fallen by 36% in the last decade, just short of what is needed by 2030. Taking antiviral tablets for 8 to 12 weeks can cure more than 95% of cases. Initiatives including A&E blood tests, GP registration testing and free at-home tests have helped to find people who were previously undiagnosed, says NHS England. NHS England says that since 2015, more than 100,000 people have been diagnosed and treated for hepatitis C, meaning the country is already meeting that target. Another goal -- a 65% reduction in hepatitis C-related mortality compared with 2015 levels -- has yet to be met, but might be before the 2030 target date. Around 50,200 adults are living with hepatitis C, figures for England in 2024 suggest. Estimates indicate 84.6% of those living with hepatitis C have been diagnosed -- just short of the 90% target. The Hepatitis C Trust says England is "on the cusp" of one of the most significant public health achievements in our country's history.

Read more of this story at Slashdot.

alternative_right shares a report from ScienceAlert: [I]n a new study published in the Journal of Cognitive Neuroscience, researchers from Georgetown University Medical Center in the U.S. have revealed that we can put certain tasks on autopilot in a way that enables something closer to true multitasking. Driving is the perfect example: When you take your test, your entire mental and physical energy is concentrated on executing the right combinations of movements and thoughts. After a decade behind the wheel, the brain is no longer consciously thinking everything through in great detail. In the new study, the researchers found that after extensive practice, the brain can effectively reroute some tasks around the brain's main computing center -- like a bypass road around a city -- to reduce mental overload and improve multitasking capability. "We have another stepping stone in our understanding of how the brain learns," says neuroscientist Maximilian Riesenhuber, senior author of the study. "The encouraging part is that you really can learn to multitask. There is actually a way to remodel your brain architecture and use other parts of your brain." [...] "Previous studies have shown that parts of the temporal cortex can be activated by particular object categories in experienced observers -- birds, cars, even Pokemon -- but a limitation of all of those studies is that they only looked after people became experts," says psychologist Patrick Cox, first author of the study. "We measure before and after training, so we can see that extensive training essentially put a category-selective area in the temporal lobe that was not there before." The study culminated in a dual-task experiment, in which the participants were asked to identify cars and take on another challenge. The individuals whose brains had offloaded more car-sorting work to the temporal cortex did better at the second task.

Read more of this story at Slashdot.

A large Danish study found a modest but consistent association between long-term road traffic noise exposure and higher Parkinson's disease risk, with a 3% increase for every 11.5 dB rise in noise at the most exposed side of a home. The Guardian reports: The researchers modeled noise exposure at the most and least exposed exterior of the residence of each participant and calculated the difference in noise levels. The magnitude of the effect was modest but consistent; at the most exposed facade, for every 11.5dB rise in noise level, the risk of Parkinson's disease rose by 3% over the study period. Having a quiet part of the home may mitigate the association between exposure to road traffic noise and higher risk of Parkinson's disease, according to the findings. The study, published in Jama Neurology, included 3.1 million Danish participants aged 40 and over, and followed them for 18 years. It was established using nationwide health register data, making it the largest study on road traffic noise and Parkinson's disease. Previous research linked the rise in neurological disorders, including Parkinson's disease, with exposure to environmental toxins. Environmental risk factors such as air pollution, microplastics and pesticides have become the main focus of prevention strategies. The study is one of the first to make the link to noise pollution.

Read more of this story at Slashdot.